ARK Investment Management LLC Has $146.17 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

ARK Investment Management LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,536,386 shares of the company's stock after buying an additional 280,946 shares during the quarter. Intellia Therapeutics makes up approximately 1.2% of ARK Investment Management LLC's investment portfolio, making the stock its 25th largest position. ARK Investment Management LLC owned approximately 12.31% of Intellia Therapeutics worth $146,174,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of NTLA. Blue Trust Inc. grew its position in shares of Intellia Therapeutics by 182.7% in the third quarter. Blue Trust Inc. now owns 4,189 shares of the company's stock valued at $94,000 after purchasing an additional 2,707 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after purchasing an additional 794 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Intellia Therapeutics by 72.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,537 shares of the company's stock valued at $401,000 after purchasing an additional 8,204 shares during the last quarter. SteelPeak Wealth LLC acquired a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $393,000. Finally, Harbor Capital Advisors Inc. grew its position in shares of Intellia Therapeutics by 71.0% in the third quarter. Harbor Capital Advisors Inc. now owns 79,205 shares of the company's stock valued at $1,628,000 after purchasing an additional 32,893 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NTLA. The Goldman Sachs Group reaffirmed a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday. Citigroup boosted their price target on Intellia Therapeutics from $12.00 to $14.00 and gave the company a "neutral" rating in a research note on Friday. Barclays cut their price target on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday. BMO Capital Markets cut their price target on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Finally, StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of "Moderate Buy" and an average price target of $42.12.

Intellia Therapeutics Trading Down 7.1 %

NASDAQ NTLA traded down $0.77 on Friday, hitting $10.09. 4,575,164 shares of the company's stock were exchanged, compared to its average volume of 3,297,134. The stock has a 50-day moving average of $10.85 and a 200-day moving average of $15.64. Intellia Therapeutics, Inc. has a 52 week low of $8.96 and a 52 week high of $34.87. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -1.85 and a beta of 1.80.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.